Department of Urology, Korea University School of Medicine.
Ther Adv Urol. 2013 Apr;5(2):101-10. doi: 10.1177/1756287212470019.
Udenafil is a potent novel phosphodiesterase-5 inhibitor approved for use in Korea. Udenafil has unique properties, with a T max of 1.0-1.5 h and a T 1/2 of 11-13 h (a relatively rapid onset and a long duration of action). Therefore, both on-demand and once-daily use of udenafil have been reported. Udenafil's efficacy and tolerability have been evaluated in several studies, and recent and continuing studies have demonstrated udenafil's promise in both dosing regimens. Presently, tadalafil is the only FDA-approved drug for daily dosing, but udenafil can be used as a once-daily dose for erectile dysfunction patients who cannot tolerate tadalafil due to phosphodiesterase subtype selectivity. Udenafil as an on-demand or once-daily dose is effective and tolerable, but more studies are needed in patients of other ethnicities and with comorbid conditions such as diabetes mellitus, hypertension, and benign prostate hyperplasia.
乌地那非是一种新型的磷酸二酯酶-5 抑制剂，在韩国被批准使用。乌地那非具有独特的特性，其 T max 为 1.0-1.5 小时，半衰期为 11-13 小时（起效较快，作用持续时间较长）。因此，已报道按需和每日一次使用乌地那非。几项研究评估了乌地那非的疗效和耐受性，最近和正在进行的研究表明，乌地那非在两种给药方案中均有应用前景。目前，他达拉非是唯一获得 FDA 批准的每日剂量药物，但对于由于磷酸二酯酶亚型选择性而不能耐受他达拉非的勃起功能障碍患者，乌地那非可以作为每日一次的剂量使用。乌地那非作为按需或每日一次的剂量是有效且耐受良好的，但在其他种族的患者和患有糖尿病、高血压和良性前列腺增生等合并症的患者中，还需要更多的研究。
